Muraglitazar (Pargluva), a dual alpha/gamma PPAR activator, has both glucose and lipid lowering effects in animal models and in patients with diabetes. This study describes the in vivo and in vitro comparative metabolism of [ 14 C]muraglitazar in rats, dogs, monkeys, and humans by quantitative and qualitative metabolite profiling. Metabolite identification and quantification methods used in these studies included LC/MS, LC/MS/MS, LC/radiodetection, LC/UV, and a newly described mass defect filtering technique in conjunction with high resolution MS. Following oral administration of [ 14 C]muraglitazar, absorption was rapid in all species, reaching a concentration peak for parent and total radioactivity in plasma within 1 hour. The most abundant component in plasma at all times in all species was the parent drug, and no metabolite was present in greater than 2.5% of the muraglitazar concentrations at 1 hour post dose in rats, dogs, and humans. All metabolites observed in humans plasma were also present in rats, dogs, or monkeys. Urinary excretion of radioactivity was low (<5% of the dose) in all intact species and the primary route of elimination was via biliary excretion in rats, monkeys, and humans. Based on recovered doses in urine and bile, muraglitazar showed a very good absorption in rats, monkeys, and humans. The major drug-related components in bile of rats, monkeys, and humans were glucuronides of muraglitazar and its oxidative metabolites. The parent compound was a minor component in bile, suggesting extensive metabolism of the drug. In contrast, the parent drug and oxidative metabolites were the major components in feces and no glucuronide conjugates were found, suggesting that glucuronide metabolites were excreted in bile and hydrolyzed in the gastrointestinal tract. The metabolites of muraglitazar resulted from both glucuronidation and oxidation. The metabolites in general had greatly reduced activity as PPARα/γ activators relative to muraglitazar. In conclusion, muraglitazar was rapidly absorbed, extensively metabolized through glucuronidation and oxidation, and mainly eliminated in the feces via biliary excretion of glucuronide metabolites in all species studied. Disposition and metabolic pathways were qualitatively similar in rats, dogs, monkeys, and humans.
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INTRODUCTION
The peroxisome proliferator-activated receptors (PPARs) are a set of nuclear hormone receptors. The two most intensively investigated subtypes have been PPARα (expressed primarily in the liver and plays a critical role in lipid metabolism) and PPARγ (predominantly expressed in adipose tissue and implicated in insulin sensitization as well glucose and fatty acid utilization). PPARα is the target of the fibrate class of hypolipidemic drugs such as fenofibrate (Balfour et al., 1990; Despres, 2001 ) and gemfibrozil (Packard et al., 2002) , whereas PPARγ is the target of the thiazolidinedione (Mudaliar and Herry, 2001 ) class of antidiabetic drugs such as rosiglitazone (Balfour and Plosker, 1999; Cheng-Lai and Levine, 2000; Goldstein, 2000) and pioglitazone (Gillies and Dunn, 2000) . a novel dual PPAR α/γ activator, is an oxybenzylglycine analog (non-thiazolidinedione) and has both glucose and lipid lowering effects when tested in animal models of diabetes and dyslipidemia and in patients with diabetes (Devasthale et al., 2005; Harrity et al., 2006; Kendall et al., 2006) . Seventeen human oxidative metabolites of muraglitazar were identified following oral administration of [ 14 C]muraglitazar (Zhang et al., 2006 ) and glucuronidation was the major clearance pathway of muraglitazar in humans (Wang et al., 2006) . This study was conducted to determine comparative metabolite profiles quantitatively and qualitatively in plasma, urine, bile and feces from rats, dogs, monkeys, and humans following oral administration of [ 14 C]muraglitazar and in incubations with hepatocytes from mice, rats, monkeys, and humans. Seven identified metabolites were synthesized for verification and tested for their PPAR α/γ activation activity. Qualitative and quantitative profiling provides identities, amounts (or concentrations), and changes versus time of muraglitazar and its metabolites in plasma and in excreta (urine, bile, and feces) of rats, dogs, monkeys, and humans. The recently published biotransformation of [ 14 C]muraglitazar in mice (Li et al., 2006) was included in some sections for species comparison.
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6 millirem based on the tissue distribution study in rats (data not shown). This level is >75 times lower than the annual allowable exposure limit. Therefore, the administration of 100 µCi of and 24 h-interval thereafter for 0-168 h) and feces (24 h intervals for 0-168 h) were collected from three rats on dry-ice. In a separate biotransformation study, bile, urine, and feces (0-24 h)
were collected from three bile duct-cannulated (BDC) male rats for 0-24 h following oral administration of [ 14 C]muraglitazar (10 mg/kg, 5 µCi/mg). For bile collection, a bile salt solution (18 mg/mL cholic acid and 1.1 mg/mL sodium bicarbonate in saline, pH 7.2) was infused via the duodenal cannula at 1 mL/h for BDC rats. For the pharmacokinetic study, blood (300 µL) was collected from three rats via a jugular vein cannula at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 , and 168 h post dose.
Mouse. Bile, urine, and feces were collected (0-24 h) from 5 bile-duct cannulated male CD-1 mice following an oral dose of [ 14 C]muraglitazar (1 and 40 mg/kg, 11.2 µCi/mg). For bile collection, a solution of taurocholic acid (2.3 mg/mL in 0.9% saline) was infused via the duodenal cannula at 0.3 mL/h for BDC mice (Li et al., 2006) .
Dog. Blood (10 mL at 1, 4, and 12 h) was collected from the indwelling venous catheter from three male beagle dogs following oral doses of [ 14 C]muraglitazar (1.9 mg/kg, 2.8 µCi/mg). Urine (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) , and 24 h-intervals thereafter for 0-168 h) and feces (24 h intervals for 0-168 h) were also collected on dry-ice. In addition, another series of blood samples (2 mL) were collected at 0, This article has not been copyedited and formatted. The final version may differ from this version. 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 , and 168 h post dose for pharmacokinetic analysis.
Monkey. Blood (5 mL at 1, 4, and 12 h) was collected from the indwelling venous catheter from three male cynomolgus monkeys following oral doses of [ 14 C]muraglitazar (2 mg/kg, 6.6 µCi/mg). Urine (0-12, 12-24 h, and 24 h-interval thereafter for 0-168 h) and feces (24 h intervals for 0-168 h) were also collected on dry-ice. In a separate study, bile, urine, and feces were collected (0-8, 8-24, 24-48 h for 0-48 h) from three bile-duct cannulated male cynomolgus monkeys following an oral dose of [ 14 C]muraglitazar (5 mg/kg, 6 µCi/mg). For bile collection, a bile salt solution (18 mg/mL cholic acid and 1.1 mg/mL sodium bicarbonate in saline, pH 7.2) was administered via a distal (flushing) catheter at 1 mL/kg/h for BDC monkeys. In addition,
another series of blood samples (2 mL) were collected at 0, 0. 25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 , and 168 h post dose for pharmacokinetic analysis.
Human. Blood (10 mL at 1, 4, and 12 h) was obtained by venipuncture from six healthy male subjects following a single 10-mg oral dose of 100 µCi. Urine (0-8, 8-24 h, and 24 h-interval thereafter for 0-240 h) and feces (24 h intervals for 0-240 h) were obtained. In addition, another series of blood samples (2 mL) were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 , and 168 h post dose for pharmacokinetic analysis. Bile was collected over 3-8 h post dose from 4 subjects following an oral 20 mg (100 µCi) dose of [ 14 C]muraglitazar (Wang et al., 2006 ).
An intravenous dose of cholecystokinin was used to stimulate gallbladder contraction at 7 h post dose in humans.
To stabilize acylglucuronide metabolites in bile samples, acetic acid was added to 2 or 5% (v/v) after bile sample collection prior to sample freezing at -20°C. The blood was collected in tubes containing K3EDTA and centrifuged within 30 min of collection to harvest plasma (10 min, 1300xg at 4°C). Animal fecal homogenate was prepared by mixing water:ethanol (50:50, v/v) and feces (5:1, w/w) followed by homogenization. A paste of human feces was prepared as homogenate before analysis for radioactivity and sample pooling. Urine and fecal homogenate were pooled by combining urine and feces obtained during each collection interval (1% for feces and 2% for urine). A pooled plasma sample was prepared by combining equal volumes of plasma
(1-2 mL) from all subjects for each collection time point. Pooled plasma, urine, and feces were analyzed for radioactivity distribution and metabolite identification by LC/MS/MS. A description of the studies and recovery of radioactive doses in animals and humans are shown in Table 1 . The dose recovery data from humans with bile collection were presented previously and are included here for comparison (Wang et al., 2006) .
Incubations of [ 14 C]Muraglitazar in Hepatocytes
Cryopreserved hepatocytes from monkeys and humans were thawed as recommended by the µg/mL) in buffer served as a negative control. At the end of the incubations, acetonitrile (2 mL) was added to each sample, and the mixtures were sonicated for 5 min in a Branson 5210
sonicator. The samples were centrifuged at 3000xg for 10 min. The supernatants were removed and aliquots were taken for radioactivity counting. The radioactivity recoveries were 95.6, 96.5, 99.2, and 98.7%, respectively, from mouse, rat, monkey, and human hepatocyte incubations. The remainder of supernatant was evaporated to near dryness under a stream of nitrogen. The residues were reconstituted in 0.2 mL of water/acetonitrile (2:1, v/v) for HPLC/UV, LC/MS/MS, and LC/radiodetection.
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Radioactivity Analysis and High-Performance Liquid Chromatography (HPLC)
The radioactivity detection and HPLC analysis were performed as described previously (Zhang et al., 2006) . Under these conditions, the synthetic metabolite standards, M1, M5, M9, M10, M11, M15, M16, each had the same retention times (monitored by UV at 275 nm) as the corresponding metabolites in the human fecal extract (monitored by radioactivity detection).
These metabolite standards also had the same MS fragmentation patterns as the in vivo metabolites.
Preparation of Biological Samples for Metabolite Profiling
Plasma. Pooled plasma was extracted by addition of 2 mL of acetonitrile to 1 mL of plasma, vortexed for 1 min, and centrifuged at 2000xg for 10 min (Eppendorf 5810 R centrifuge, Eppendorf Company, Hamburg, Germany). The supernatant was removed and saved. The pellet was treated with additional three extractions with 2 mL of acetonitrile/water (2:1, v/v) and all supernatants were combined. Aliquots of 100-300 µL of this solution were mixed with Ecolite cocktail and counted for radioactivity. After the solvent was evaporated to dryness under nitrogen, the residue was re-dissolved in 0.20 mL of water/acetonitrile (2:1, v/v) and centrifuged at 2000xg for 10 min before injecting onto the HPLC column.
Urine. Pooled urine (5 mL) was concentrated either by passing through a 5 mL C18 cartridge (Oasis, Waters) or by direct evaporation under a steam of nitrogen. The cartridge was eluted with methanol after washing with a half-column volume of water and the eluate was concentrated under a stream of nitrogen. The residue from direct evaporation of the urine or from the evaporation of the methanol eluate was suspended in 0.20 mL of water/acetonitrile (2:1, v/v) and centrifuged at 2000xg for 10 min, and the supernatant (50 µL) was subjected to HPLC analysis.
Feces. Pooled fecal homogenate was extracted by addition of 4 mL of acetonitrile to about 1 g of fecal homogenate, vortexed for 5 min, sonicated for 5 min, and centrifuged at 2000xg for 30 min.
The supernatant was removed and saved. The extraction was repeated twice with 2 mL of This article has not been copyedited and formatted. The final version may differ from this version. for 10 min. The supernatant (10-30 µL) was analyzed directly.
LC/MS for Quantification of Muraglitazar in Plasma
The method utilized trazodone as the internal standard (IS). After the addition of 0.2 mL of acetonitrile containing 100 ng/mL of IS to 0.1 mL of plasma sample, methylene chloride (0.1 mL) was added. The samples were vortexed for 2 min and then centrifuged at 14,000 rpm for 3 min. The organic phase was removed and evaporated to dryness under nitrogen at 40°C. The residue was reconstituted with 0.2 mL of HPLC mobile phase A and 20 µL of the sample was injected onto the LC/MS. Chromatographic separation was achieved on a Waters 2690 HPLC system using a BDS hypersil C18 analytical column (2 x 50 mm, 3 µm) at a flow rate of 0.3 mL/min. An isocratic system was employed using 90% mobile phase A (acetonitrile/0.1% formic acid, 50:50, v/v) and 10% mobile phase B (acetonitrile/0.1% formic acid, 95:5, v/v). Analysis (m/z 517.1 for muraglitazar and m/z 372.0 for IS) was accomplished by positive turbo ion spray on a Sciex API 100 mass spectrometer (Applied Biosystems, Beverly, MA).
Pharmacokinetic Analysis
The plasma concentration vs time data for radioactivity and unchanged muraglitazar were analyzed by a noncompartmental method (Gibaldi and Perrier, 1982) . The peak plasma concentration, C max , and the time to reach peak concentration as the first occurrence, T max , were recorded directly from experimental observations. The area under the plasma concentration vs time curve (AUC) was calculated by a combination of the trapezoidal methods. The AUC was Samples were analyzed in the positive ion mode. The capillary temperature used for the LCQ and LTQ was set at 230°C. The desolvation temperature used on the Q-TOF was 300°C. The nitrogen gas flow rate, spray and cone voltages were adjusted to give maximum sensitivity for muraglitazar. The Q-TOF was tuned to 18,000 resolution at half peak height using an insulin tuning solution, and was calibrated up to 1500 Da using a polyalanine calibration solution. For accurate mass measurement, the m/z 556.2771 of an infused 20 ng/µL leucine enkephalin solution were used as Lock Mass. The experimentally obtained masses were within 5 mDa compared to their respective calculated values.
Total Ion Chromatograms After Mass Defect Filtering Analysis
The data files from the Q-TOF high resolution mass analysis of fecal extracts of humans, monkeys, and rats were processed using the mass defect filtering method (Zhang et al., 2003) .
The centroid raw data was processed using a mass defect filter designed to retain ion species with mass defects between 0.006 and 0.106 Da in a mass range of 250-850 Da. The filter was based on the apparent mass of muraglitazar (517.1975 Da) in the uncorrected centroid raw data file.
This article has not been copyedited and formatted. The final version may differ from this version. 
Radioactivity Profiles and Quantification of Metabolites
The average CPM value from a baseline section (2-3 min) of the chromatogram was subtracted from the CPM value of each fraction. Biotransformation profiles were prepared by plotting the CPM values against time-after-injection using Microsoft ® Excel software. Radioactive peaks in the biotransformation profiles were reported as a percentage of the total radioactivity collected during the entire HPLC run. The relative distributions of radioactive metabolites in urine, bile, and feces were calculated from the percent of dose excreted in the matrix (based on DPM by scintillation counting) multiplied by the percent of distribution of metabolites in chromatograms of the matrix (based on CPM counting by Top Count).
Determination of PPARα/γ Binding and Transactivation Activities of Muraglitazar
Metabolites
The in vitro PPAR biological activity of the seven synthetic muraglitazar metabolites were evaluated and PPARα/γ binding and transactivation activity values were determined as described previously (Devasthale et al., 2005) .
RESULTS
Excretion of Radioactive Dose
The recovery values of radioactive dose in urine, bile, and feces of rats, mice, dogs, monkeys, and humans are shown in Table 1 (Wang et al., 2006) . The fecal metabolite profiles were qualitatively similar between the two human C-14 studies. It was, therefore, concluded that the metabolite profiling results from the samples of the 10-mg dose study were valid despite the lower than an anticipated recovery. Radioactivity excretion profiles of actual volumes of urine collected) in rat, monkey, and human urine during this period of urinary excretion are shown in Table 2A . The concentrations of drug-related radioactivity in rat, dog, and monkey urine were approximately 9, 1, and 3 times of that in human urine. The rate of fecal excretion in rats and dogs was rapid, with approximately 85% recovered within 24 h and nearly 95% within 48 h post dose ( Figure 1B ). In contrast, the rate of fecal excretion in monkeys was slower, with approximately 30% recovered within 48 h and 75% within 96 h post dose. The rate of fecal excretion in humans was similar to that in monkeys, with 25% within 48 h and 80%
within 96 h post dose.
The majority of the excretion of radioactivity in bile probably occurred during the first 24 to 48 hours after dose administration. The average radioactive dose recovery value in 0-24 h bile of BDC rats was 65.1% and in the corresponding feces of these rats was 0.55%. The radioactive dose recovery values in 0-48 h bile of three BDC monkeys were 15.4, 16.9, and 75.2%, and in corresponding feces of these three monkeys were 30.6, 6.7, and 7.7%. The concentrations of muraglitazar equivalents (parent drug plus metabolites) in rat, mouse, monkey, and human bile within specified collection periods are shown in Table 2B . The concentrations of drug-related radioactivity in rat, mouse, and monkey bile were approximately 4, 5.5-190, and 0.1 times of that in human bile. Human subjects seemed to show a fast biliary elimination since approximately 40% of dose was found in bile during the 3-8 h collection after dose.
Pharmacokinetic Results
The pharmacokinetic parameters for the unchanged drug and radioactivity are presented in Table   3 . The animal and human plasma concentration time profiles for radioactivity and muraglitazar are presented in Figure 2 . Following oral administration, the radioactivity and muraglitazar concentrations reached a maximum at 0.5 to 1 h in rats, dogs, monkeys, and humans. While the trends declined in dogs and humans after reaching C max , the radioactivity and muraglitazar concentrations reached a second peak at approximately 6-8 h in rats and monkeys, suggesting the This article has not been copyedited and formatted. The final version may differ from this version. potential of enterohepatic recycling of muraglitazar and radioactivity in rats and monkeys. The mean terminal elimination T 1/2 values of plasma radioactivity and muraglitazar were longer in monkeys and humans (18-35 h) than those from rats and dogs (4-10 h). The longer T 1/2 values for the parent compound relative to total radioactivity in rats, dogs, and humans were probably due to truncation of the radioactivity AUC curves due to lower assay sensitivity of radioactivity compared to LC/MS-based parent determination. The overall kinetic profiles and AUC values for radioactivity are similar to those of muraglitazar in all species. Table 4 shows the proposed structures for the muraglitazar metabolites identified in rats, dogs, Metabolite M23: From hepatocyte incubations, 5-methyl-2-phenyl oxazoyl-4-acetic acid was also identified as a non-radiolabeled metabolite resulting from the dealkylation of muraglitazar.
Identification of [ 14 C]Muraglitazar Metabolites
This metabolite had a measured accurate mass of 218.0820 and a formulae of C 12 H 12 NO 3 (expected mass of 218.0817). M23 was identified as 5-methyl-2-phenyl oxazoyl-4-acetic acid.
The same dealkylation reaction also produced M1.
Metabolite Profiles in Plasma
The extraction recovery of radioactivity from all plasma samples was >98%. The HPLC radiochromatographic profiles of 1-h plasma from rat, dog, monkey, and human are shown in Figure 3 . The relative distribution of radioactive metabolites in pooled plasma is summarized in Table 5 . The metabolic profiles of plasma were qualitatively similar at different time points within species and across species. Muraglitazar was the major component at 1, 4 and 12 h, accounting for more than 85% of plasma radioactivity at 1 h in all four species.
The prominent metabolite in rat plasma was M15 which accounted for 2-4% of the sample radioactivity. Several metabolites were in rat plasma and each accounted for less than 0.4% of the radioactivity. The parent compound in dog plasma represented 90.5% at 1 h, 81.3% at 4 h, and 33.0% at 12 h of the sample radioactivity. Prominent metabolites in dog plasma included M1, M5, M15, and M20. Major metabolites in monkey plasma were M5, M11, and M18. M11
accounted for 8.0% of the plasma radioactivity at 1 h, and increased to 16.3% at 4 h and 21.4% at 12 h. M5 accounted for 1.5-2.9% of the plasma radioactivity. Metabolite M18 represented 3-4%
of plasma radioactivity at 4 and 12 h in monkeys. Other metabolites observed in monkey plasma This article has not been copyedited and formatted. The final version may differ from this version. were minor. M13 was a major metabolite in human plasma, but no metabolite accounted for more than 4.5% of the plasma radioactivity at all time points. Similarly, the parent drug was the major circulating drug-related component in mice (Li et al., 2006) . All metabolites (M1, M2, M5, M8, M8a, M10-13, M15, and M18) observed in human plasma were also present in rats, dogs, or monkeys.
Metabolite Profiles in Urine
Urinary excretion was a minor pathway, representing less than 5% of the dose in all studied intact species following oral administration of [ 14 C]muraglitazar. The HPLC radiochromatographic profiles of pooled urine from rats, dogs, monkeys, and humans are shown in Figure 4 and metabolite distribution in rat, dog, monkey, and human urine was listed in Table 6 . Several very minor components (0.3 to 0.8% of the dose) were not sufficiently abundant for characterization.
Rat urine contained many radioactive peaks. The prominent rat urinary metabolites included M1, M2, M10, M15 and M21. One major radioactive peak M1 was observed in dog urine. Metabolites M1, M21, and M11 were prominent radioactive peaks in monkey urine, accounting for about 1, 0.3, 0.6% of the dose, respectively. The low level of radioactivity in human urine was distributed in several radioactive peaks, of which the glucuronide M13 accounted for 1% of the dose and the parent accounted for 0.3% of the dose. All human urinary metabolites were found in animal urine samples.
Metabolite Profiles in Feces
Feces was the major elimination route following oral administration of [ 14 C]muraglitazar to intact species. The HPLC radiochromatographic profiles of pooled feces are shown in Figure 5 and metabolite distribution in rat, dog, monkey, and human feces was listed in Table 6 . Muraglitazar was one of the abundant components present in feces from all species. The most abundant metabolite was different in each species; however, each of these metabolites were hydroxylated and O-demethylated products found in the plasma of that species.
This article has not been copyedited and formatted. The final version may differ from this version. represented approximately 40% of the sample radioactivity that was higher than that in 0-240 h pooled human feces (data not shown).
Metabolite Profiles in Bile Samples
The HPLC-radiochromatograms of pooled bile samples from rats, monkeys, and humans are shown in Figure 6 . Within 24 h following oral administration of [ 14 C]muraglitazar to BDC rats, 65% of the dose was excreted in bile and <1% of the dose was excreted in feces. The parent drug represented <5% of the dose in the rat bile, suggesting extensive metabolism of muraglitazar in rats. The glucuronide of O-demethyl muraglitazar (M20), the glucuronide of muraglitazar (M13),
and O-demethyl muraglitazar (M15) were the major metabolites in rat bile, each accounting for 11-40% of the dose (Figure 6 ). Under the conditions used for for sample collection and storage (2-5% acetic acid), the acylglucuronide metabolites appeared to be chromatographically separated as single peaks, which suggesting that minimal acyl migration occurred. Similarly, muraglitazar glucuronide (M13) was also a major metabolite in the mouse bile but was not found in the BDC mouse feces (Li et al., 2006) . In addition to those metabolites (M1-M21) identified in other species (rats, dogs, monkeys, and humans), unique metabolites identified in mice included the taurine conjugates of muraglitazar and its metabolites formed from Odemethylation, hydroxylation and dihydroxylation, and glutathione conjugates (Li et al., 2006) .
Metabolite Profiles in Hepatocyte Incubations
The distribution of radioactive peaks presented in each hepatocyte incubation is summarized in were obtained from the incubations with hepatocytes from mice, rats, and monkeys. Figure 7 shows the LC/UV profiles of Figure 8 shows the ion chromatograms of total mass spectral signals versus HPLC run time after mass defect filtering treatment of LC/accurate mass analysis of human, monkey, and rat feces.
LC/MS Profiling of Muraglitazar Metabolites
The relative intensity of the total ion peak of each metabolite and the parent resemble qualitatively those peaks in the radiochromatograms of these samples. Full scan mass spectra and MS/MS spectra were derived from these ion chromatograms for identification of metabolites.
MDF-treated total ion chromatograms were specially useful to identify molecular ions of each metabolite due to the effective removal of endogenous interfering ions (Zhang et al., 2003) . 
PPAR α/γ Activities of Muraglitazar Metabolites
DISCUSSION
Following oral administration of [ 14 C]muraglitazar, the parent compound was the major circulating component in plasma of rats, dogs, monkeys, and humans. AUC values for muraglitazar and total radioactivity are similar in rats, dogs, and humans although the parent AUC represented approximately 40% of the radioactivity AUC in monkeys, suggesting that the radioactivity was mainly attributed to parent compound. HPLC/radioactivity profiling of selected plasma samples confirmed that muraglitazar was the major circulating component and there were limited amounts of circulating metabolites. Biliary elimination followed by fecal excretion was the major elimination pathway in all species while urinary elimination was minor. All human metabolites were found in samples from at least one of the toxicological animals (rats or monkeys). The metabolic pathways of muraglitazar included glucuronidation, aliphatic/aryl hydroxylation, O-deakylation, a combination of O-demethylation and hydroxylation, and oxazole-ring opening. Although the mechanism is not known, oxazole-ring opening appeared to lead to the formation of two stable metabolites, M9 and M16, in all species tested. Both muraglitazar glucuronide (M13) and O-demthyl muraglitazar gluucronide (M20) were major metabolites in the bile of BDC rats. Muraglitazar glucuronide (M13) was the major metabolite in the bile of BDC monkeys. However, oxidative metabolites were predominant in feces of intact animals, suggesting that the glucuronides were hydrolyzed in the intestine. Similarly, most of the radioactive components in human bile were glucuronide metabolites, while oxidative metabolites were found in human feces (Wang et al., 2005) . The biliary excretion and intestinal hydrolysis of the glucuronide metabolites provide a potential for enterohepatic recycling of muraglitazar and its oxidative metabolites. However, no obvious evidence for this process was observed in the plasma radioactivity time profiles for humans and dogs, although a second peak for both muraglitazar and total radioactivity appeared at 6-8 h post dose in rats and monkeys. The second peak for the parent and radioactivity in rats is likely not due to enterohepatic recirculation as the rat is a This article has not been copyedited and formatted. The final version may differ from this version. When muragliatzar was incubated with hepatocytes of mice, rats, monkeys, and humans at a concentration of 2-10X C max values determined in these species, the majority of metabolites resulted from oxidation pathways including hydroxylation and O-demethylation which were also observed in vivo. A relatively small fraction of metabolites resulted from glucuronidation to form M13 and M18 in these hepatocyte incubations, which underestimated the in vivo importance of the glucucronidation pathway. This is likely due to the instability of the glucuronide metabolite in the hepatocyte incubations. In contrast, the glucuronide metabolites in plasma and bile samples were relatively stable under the acidified and low temperature conditions.
In general, both quantitative and qualitative metabolite profiles are important to understand the relative abundance and identities of metabolites in various matrices from different species. The metabolites of muraglitazar in plasma, urine, feces, and bile as well as hepatocyte incubations were profiled quantitatively and qualitatively through LC/radioactivity detection, LC/UV, LC/MS, and LC/MS/MS analysis. Metabolites identified in each species were assigned as same structure based on HPLC retention time and MS/MS spectral properties. Qualitatively and quantitatively similar metabolite profiles of muraglitazar in rats, dogs, monkeys, and humans support that these animal species were valid models to evaluate the safety profile of muraglitazar.
Mass defect filtering analysis not only generates metabolite identification data (mass spectra with minimal endogenous interferences) (Zhang et al., 2003) , but also provides total ion chromatograms that qualitatively resemble the metabolite radiochromatograms of fecal extracts of human, monkeys, and rats ( Figure 8 ). Although total ion chromatograms obtained after the mass defect filtering analysis of high resolution MS data, representing mass spectral signals or total ion signals acquired at each time point plotted against HPLC run time, resemble the radiochromatograms of human, monkey, and rat feces, these ion chromatograms should not be used to fully quantify the amounts of metabolites. However, the close resemble to the radiochromatograms of the fecal samples provides the first potentially useful LC/MS-based estimation method for relative abundance of metabolites. This metabolite quantity estimation method would be specially useful when a validated quantitation method is not available yet quantity information is important to know in certain phases of drug development such as the firstin-man study for metabolite profile in plasma. Therefore, LC/high resolution MS and LC/MS/MS methods were complementary to quantitative profiling using radioactivity detection when the existence of a metabolite need to be qualified.
In summary, the current study describes the disposition and comparative metabolism of and conjugative pathways, and eliminated mainly through biliary excretion as glucuronide conjugates of the parent and its oxidative metabolites.
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This article has not been copyedited and formatted. The final version may differ from this version. (2002) Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. ]muraglitazar used was: 8.4 and 5 µCi/mg for rats, 11.2 µCi/mg for mice, 2.8 µCi/mg for dogs, 6.6 and 6 µCi/mg for monkeys, and 10 and 5 µCi/mg for humans.
b The human and mouse data with bile collection were presented previously (Wang et al., 2006; Li et al., 2006) and were included here to allow a complete species comparison. a Units for C max : muraglitazar (µg/mL) and radioactivity (µg-equivalents/mL); Units for AUC: muraglitazar (µg• h/mL) and radioactivity (µg-equivalents• h/mL). Last detectable time points for respective parent compound and the radioactivity were 96 and 24 h for rat, 12 and 4 h in dog, 144 and 24 h for monkey, and 192 and 72 h for human.
b The T 1/2 values for radioactivity were lower than the parent for rats, dogs, and monkeys because the detection limit for radioactivity was approximately 15-30 times higher than LC/MS-based parent determination.
c Not determined due to limited time points.
d Second peaks were observed at 8 h in rats.
e Second peaks were observed for at 6 h in monkeys.
